



## **Mark Lanasa, M.D., Ph.D.**

*Senior Vice President, Chief Medical Officer, Solid Tumors*

*Mark Lanasa, M.D., Ph.D., joined BeOne, formerly BeiGene, in February 2022 as Senior Vice President, Chief Medical Officer for Solid Tumors.*

*Prior to joining BeOne, Dr. Lanasa served as Vice President and Global Clinical Head, Late Development Oncology, at AstraZeneca. He previously held several positions at AstraZeneca, including Global Clinical Lead and Global Development Lead for Immuno-Oncology, Senior Medical Director in Clinical Development and Medical Director in Early Clinical Development. Dr. Lanasa also served as Senior Director of Clinical Development at Immunocore, where he contributed to the late-phase development of T-cell engager Kimmtrak® (tebentafusp-tebn).*

*Dr. Lanasa earned a B.S. in chemistry from The Pennsylvania State University and both a Ph.D. in biochemistry and molecular genetics and an M.D. in the Medical Scientist Training Program at the University of Pittsburgh School of Medicine. He completed his residency and was a postgraduate fellow at the Duke University Medical Center, where he was subsequently on the faculty specializing in the treatment of hematologic malignancies.*

## **Mark Lanasa, M.D., Ph.D.**

*Senior Vice President, Chief Medical Officer, Solid Tumors*

*Joined BeOne: February 2022*

### **Education:**

*Pennsylvania State University  
B.S. in chemistry*

*University of Pittsburgh School of  
Medicine*

*Ph.D. in biochemistry and molecular  
genetics*

*M.D. in the Medical Scientist Training  
Program at the*